Vertex Pharmaceuticals Incorporated
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of aā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$469.34
Price-1.84%
-$8.79
1Y
Price
Market Cap
$119.212b
Large
Price/Earnings 3y Avg5y Avg
31x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+41.9%
EBITDA Margin+36.9%
Net Profit Margin+10.8%
Free Cash Flow Margin+41.9%
EBITDA Margin+36.9%
Net Profit Margin+10.8%
Free Cash Flow MarginRevenue
$12.075b
+9.2%
1y CAGR+10.5%
3y CAGR+12.3%
5y CAGREarnings
$3.953b
+838.1%
1y CAGR+244.1%
3y CAGR+193.5%
5y CAGREPS
$15.32
+837.0%
1y CAGR+243.5%
3y CAGR+193.2%
5y CAGRBook Value
$18.666b
$26.143b
Assets$7.477b
Liabilities$3.883b
DebtDebt to Assets
14.9%
0.8x
Debt to EBITDAFree Cash Flow
$3.194b
+504.1%
1y CAGR+121.2%
3y CAGR+106.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company